Stocks of the Hour: QX Resources, Chimeric Therapeutics, Alliance Nickel
Stocks of the Hour: QX Resources, Chimeric Therapeutics, Alliance Nickel
To register for Friday's webinar click here.
要註冊參加週五的網絡研討會，請單擊此處。
QX Resources (ASX:QXR) announced that numerous brine aquifers were successfully intersected in the second hole of a two-hole diamond drill (DD) program over the large scale Liberty Lithium brine project in California, USA. The results and interpretations from drillhole 1 are expected in mid-February, with drillhole 2 results in late March. Shares are trading 16.67 per cent higher at 2.1 cents.
QX Resources（澳大利亞證券交易所股票代碼：QXR）宣佈，在美國加利福尼亞州的大規模Liberty Lithium鹽水項目的兩孔金剛石鑽探（DD）項目的第二洞中，成功穿透了許多鹽水含水層。1號鑽孔的結果和解釋預計將在2月中旬公佈，2號鑽孔的結果將在3月下旬公佈。股價上漲16.67％，至2.1美分。
Chimeric Therapeutics (ASX:CHM), an Australian leader in cell therapy, announced that the first patient in the ADVENT-AML Phase 1B clinical trial in Acute Myeloid Leukaemia (AML) has received treatment with CHM 0201. The trial, now open to enrolment at The University of Texas MD Anderson Cancer Center, will recruit up to 20 patients with newly diagnosed AML. Shares are trading 16 per cent higher at 2.9 cents.
澳大利亞細胞療法領域的領導者Chimeric Therapeutics（澳大利亞證券交易所股票代碼：CHM）宣佈，ADVENT-AML急性髓系白血病（AML）1B期臨床試驗的第一位患者已經接受了CHM 0201的治療。該試驗現已向德克薩斯大學醫學博士安德森癌症中心開放報名，將招募多達20名新診斷的急性髓細胞白血病患者。股價上漲16％，至2.9美分。
Alliance Nickel (ASX:AXN) has signed a non-binding term sheet with Samsung SDI for the future offtake of battery grade nickel and cobalt sulphate products from the NiWest Nickel-Cobalt Project in Western Australia. Samsung SDI and Alliance will discuss a potential acquisition by Samsung SDI of an equity interest in the NiWest Project. Shares are trading 56.67 per cent higher at 4.7 cents.
Alliance Nickel（澳大利亞證券交易所股票代碼：AXN）已與三星SDI簽署了一份不具約束力的條款表，內容涉及未來從西澳大利亞NiWest鎳鈷項目中收購電池級鎳和硫酸鈷產品。三星SDI和Alliance將討論三星SDI可能收購NiWest項目的股權。股價上漲56.67％，至4.7美分。
譯文內容由第三人軟體翻譯。